Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus

Jason Seewoodhary1, Leanne Griffin1, Stephen C Bain11Department of Diabetes and Endocrinology, Swansea School of Medicine, University of Wales, Swansea SA2 8PP, UKAbstract: Exenatide (also known as exendin-4) is a glucagon-like peptide-1 mimetic, which is indicated for the treatment of type 2 diabet...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Seewoodhary J, Griffin, Bain S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Type 2 Diabetes Exenatide QW GLP-1 mimetic HbA1C Weight loss Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/bad96351b7d74267b44ac891c70c9d99
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bad96351b7d74267b44ac891c70c9d99
record_format	dspace
spelling	oai:doaj.org-article:bad96351b7d74267b44ac891c70c9d992021-12-02T00:35:50ZCritical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus1178-7007https://doaj.org/article/bad96351b7d74267b44ac891c70c9d992010-05-01T00:00:00Zhttps://www.dovepress.com/critical-appraisal-of-once-weekly-formulation-of-exenatide-in-the-cont-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Jason Seewoodhary1, Leanne Griffin1, Stephen C Bain11Department of Diabetes and Endocrinology, Swansea School of Medicine, University of Wales, Swansea SA2 8PP, UKAbstract: Exenatide (also known as exendin-4) is a glucagon-like peptide-1 mimetic, which is indicated for the treatment of type 2 diabetes mellitus. The currently available formulation of this drug is a twice-daily exenatide (exenatide BID) injection that should be administered within 60 minutes of food. Once-weekly exenatide (exenatide QW) formulation is now being assessed in a clinical trial program. Exenatide QW has been shown to be the only noninsulin monotherapy to achieve glycosylated hemoglobin levels of <7% in >75% of treated patients. It has also demonstrated potential cardiovascular benefits by lowering total and low-density lipoprotein cholesterol concentrations, triglyceride levels, and both systolic and diastolic blood pressure. In addition, patients treated with exenatide QW achieved significant weight loss, which may also lead to significant cardiovascular risk reduction. Exenatide QW is associated with a lower incidence of gastrointestinal adverse effects compared with exenatide BID, and no patients treated with exenatide QW monotherapy experienced a confirmed hypoglycemic event. Exenatide QW results in 24-hour coverage with exenatide concentrations that are known to improve glycemic control and remain well tolerated in patients with type 2 diabetes mellitus. This review defines the state of play with exenatide QW by critically appraising its role in clinical practice.Keywords: GLP-1 mimetic, HbA1c, weight lossSeewoodhary JGriffinBain SDove Medical PressarticleType 2 DiabetesExenatide QWGLP-1 mimeticHbA1CWeight lossSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 3, Pp 165-172 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Type 2 Diabetes Exenatide QW GLP-1 mimetic HbA1C Weight loss Specialties of internal medicine RC581-951
spellingShingle	Type 2 Diabetes Exenatide QW GLP-1 mimetic HbA1C Weight loss Specialties of internal medicine RC581-951 Seewoodhary J Griffin Bain S Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
description	Jason Seewoodhary1, Leanne Griffin1, Stephen C Bain11Department of Diabetes and Endocrinology, Swansea School of Medicine, University of Wales, Swansea SA2 8PP, UKAbstract: Exenatide (also known as exendin-4) is a glucagon-like peptide-1 mimetic, which is indicated for the treatment of type 2 diabetes mellitus. The currently available formulation of this drug is a twice-daily exenatide (exenatide BID) injection that should be administered within 60 minutes of food. Once-weekly exenatide (exenatide QW) formulation is now being assessed in a clinical trial program. Exenatide QW has been shown to be the only noninsulin monotherapy to achieve glycosylated hemoglobin levels of <7% in >75% of treated patients. It has also demonstrated potential cardiovascular benefits by lowering total and low-density lipoprotein cholesterol concentrations, triglyceride levels, and both systolic and diastolic blood pressure. In addition, patients treated with exenatide QW achieved significant weight loss, which may also lead to significant cardiovascular risk reduction. Exenatide QW is associated with a lower incidence of gastrointestinal adverse effects compared with exenatide BID, and no patients treated with exenatide QW monotherapy experienced a confirmed hypoglycemic event. Exenatide QW results in 24-hour coverage with exenatide concentrations that are known to improve glycemic control and remain well tolerated in patients with type 2 diabetes mellitus. This review defines the state of play with exenatide QW by critically appraising its role in clinical practice.Keywords: GLP-1 mimetic, HbA1c, weight loss
format	article
author	Seewoodhary J Griffin Bain S
author_facet	Seewoodhary J Griffin Bain S
author_sort	Seewoodhary J
title	Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
title_short	Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
title_full	Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
title_fullStr	Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
title_full_unstemmed	Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
title_sort	critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/bad96351b7d74267b44ac891c70c9d99
work_keys_str_mv	AT seewoodharyj criticalappraisalofonceweeklyformulationofexenatideinthecontroloftype2diabetesmellitus AT griffin criticalappraisalofonceweeklyformulationofexenatideinthecontroloftype2diabetesmellitus AT bains criticalappraisalofonceweeklyformulationofexenatideinthecontroloftype2diabetesmellitus
_version_	1718403642549075968

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus

Ejemplares similares